Association of CT-defined sarcopenia with survival and therapeutic response in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis
CT-defined sarcopenia was significantly associated with poorer survival and therapeutic response among HCC patients receiving TACE and patients with sarcopenia were more likely to experience worse survival and therapeutic response.
Abstract
The prognostic impact of CT-defined sarcopenia in hepatocellular carcinoma (HCC) patients who received the transarterial chemoembolization (TACE) remains unclear. This study aimed to clarify the impact of CT-defined sarcopenia on survival and therapeutic response in HCC patients receiving TACE.
PubMed, Web of Science and CNKI databases were searched up to April 18, 2026. Primary endpoints included the overall survival (OS) and progression-free survival (PFS) and secondary endpoints were objective response rate (ORR) and disease control rate (DCR). Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were combined to evaluate the impact of CT-defined sarcopenia on primary and secondary endpoints.
Sixteen studies with 3359 cases were included. As for primary outcomes, the presence of CT-defined sarcopenia was significantly related to poorer OS (HR = 1.79, 95% CI: 1.47–2.18, P < 0.001) and PFS (HR = 1.65, 95% CI: 1.42–1.92, P < 0.001). Besides, subgroup analysis stratified by the country, sample size, combination of other therapies, source of HR and defining method of sarcopenia manifested similar findings. As for secondary outcomes, CT-defined sarcopenia was also associated with decreased ORR (OR = 0.55, 95% CI: 0.38–0.81, P = 0.002) and DCR (OR = 0.50, 95% CI: 0.37–0.67, P < 0.001).
CT-defined sarcopenia was significantly associated with poorer survival and therapeutic response among HCC patients receiving TACE and patients with sarcopenia were more likely to experience worse survival and therapeutic response.
Sarcopenia is increasingly recognized as a potential prognostic factor in patients with cancer, but its clinical significance in HR+/HER2− metastatic breast cancer treated with CDK4/6 inhibitors remains uncertain. This study investigated the association between CT-defined sarcopenia and clinical outcomes in this po...
Zeynep Alaca Topçu, Zehra Sucuoğlu İşleyen, Ismail Yurtsever et al.· Frontiers in Medicine· 0 citations
Preoperative systemic inflammatory markers are inexpensive candidate prognostic factors after hepatocellular carcinoma (HCC) resection, but heterogeneous populations, endpoints, effect measures, and cutoff selection may limit interpretation. Full texts were re-screened using a strict definition of primary HCC treated b...
Jian-Guo Chen, Hong-Yang Han, Guang-Wei Yang et al.· Scientific Reports· 0 citations
In patients with BCLC stage B HCC receiving TACE combined with systemic therapy, complete ablation was associated with improved survival and a model to identify patients most likely to benefit from the treatment was developed.
Y. Xiong, Chen Wang, Ting-Ting Mei et al.· Discover Oncology· 0 citations
The suggested dual-center nomogram shows excellent practical relevance in assessing the effectiveness of PA-TACE and improving postoperative care techniques, and integrates CT radiomics and serological markers, with overall survival as the major outcome.
Jin-Yi Liu, Qiang Xu, Qian Song et al.· Cancer Biotherapy and Radiop...· 0 citations
Background
To compare the efficacy and safety of transarterial chemoembolization (TACE) plus sintilimab and bevacizumab (triple therapy) versus sintilimab and bevacizumab alone (dual therapy) in unresectable hepatocellular carcinoma (uHCC).
Methods
This single-center retrospective cohort study enrolled consecutive pa...
Zi-Zhuo Wang, Bai-Lu Wu, Chun-Shu Wu et al.· Frontiers in Immunology· 0 citations
Transcatheter arterial chemoembolization (TACE) induces tumor necrosis and antigen release, but the resulting hypoxic microenvironment upregulates programmed death-ligand 1and vascular endothelial growth factor, providing a biological rationale for adding a programmed death-1 (PD-1) inhibitor and a TKI. The study aims...
Guo-Hui Xu, Jian-Long Zhang, Xiao-Jun Li et al.· Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.